<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Reirradiation for locally recurrent head and neck cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Reirradiation for locally recurrent head and neck cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Reirradiation for locally recurrent head and neck cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael T Milano, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph K Salama, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Haraf, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Brizel, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Despite advances in the treatment of head and neck cancer, 15 to 50 percent of patients will develop recurrent disease [<a href="#rid1">1-6</a>]. Survivors also are at risk to develop second primary tumors, the incidence of which is estimated at 8 to 22 percent, with approximately one-third occurring in the head and neck. (See  <a class="medical medical_review" href="/d/html/3405.html" rel="external">"Second primary malignancies in patients with head and neck cancers"</a>.)</p><p>Therapeutic options are limited for patients who present with locally recurrent disease or a second primary tumor in a previously irradiated field. Surgical salvage with a curative-intent resection is the preferred option for those with limited-volume disease [<a href="#rid7">7-9</a>]. Reirradiation is an alternative for patients who are not candidates for surgical salvage [<a href="#rid9">9,10</a>].</p><p>Reirradiation with or without the addition of chemotherapy may hold promise for long-term survival for appropriately selected patients. Indications for reirradiation may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who undergo surgical salvage but are found to have high-risk features.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are medically suitable for curative-intent interventions but are not amenable to curative-intent resection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are not candidates for curative-intent interventions but may benefit from palliative treatment.</p><p></p><p>General principles of treatment for locally recurrent and second primary head and neck cancer are discussed separately. Recurrence of nasopharynx cancer has a markedly better prognosis than other head and neck sites, and its management is also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3373.html" rel="external">"Treatment of locally recurrent squamous cell carcinoma of the head and neck"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3405.html" rel="external">"Second primary malignancies in patients with head and neck cancers"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3372.html" rel="external">"Treatment of early and locoregionally advanced nasopharyngeal carcinoma"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H798962322"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>Patient selection is critical since reirradiation, with or without chemotherapy, is associated with considerable acute and late toxicity (<a class="graphic graphic_algorithm graphicRef112884" href="/d/graphic/112884.html" rel="external">algorithm 1</a>) [<a href="#rid9">9,11,12</a>], although more modern radiation techniques may have lowered toxicity risks compared with historic controls [<a href="#rid13">13</a>]. Patient selection is based on tumor characteristics as well as an assessment of the patients' prognosis and their ability and willingness to tolerate the anticipated toxicity of these regimens. Patients who recur within the high-dose radiation area less than six months after the first course of radiation therapy (RT) generally have radiation-resistant disease and are not usually considered candidates for a second course of RT.</p><p>Tissues of the head and neck such as skin, nerves, blood vessels, and spinal cord normally receive significant radiation doses during the initial course of RT. Reirradiation exposes these tissues to further radiation and thereby incurs a risk of severe complications such as carotid artery stenosis or rupture, osteoradionecrosis, pharyngocutaneous fistulas, nonhealing skin ulcers, and spinal cord damage. This risk is likely reduced in the contemporary era given that most initial radiation courses are now delivered with conformal intensity-modulated radiation therapy (IMRT) sparing full-dose irradiation of tissues in close proximity. (See  <a class="medical medical_review" href="/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer"</a> and  <a class="medical medical_review" href="/d/html/3365.html" rel="external">"Management of late complications of head and neck cancer and its treatment"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Radioresistance</span><span class="headingEndMark"> — </span>The development of a tumor recurrence in a previously irradiated field suggests the existence of a radioresistant clone that would limit the therapeutic effect of reirradiation. The initial disease-free interval plays an important role in the decision of whether or not to reirradiate. Patients with tumor recurrence within six months after the first course of RT are generally thought to have radiation-resistant disease and therefore to be unlikely to benefit from a second course of RT.</p><p>The problem of radioresistance may be particularly relevant to patients who develop local recurrence after initial treatment with concurrent chemoradiotherapy [<a href="#rid14">14</a>]. Strategies to overcome radioresistance include the addition of radiation sensitizers, such as chemotherapy and targeted agents, and dose escalation or intensification, with techniques such as hyperfractionation, accelerated fractionation, conformal RT, and brachytherapy [<a href="#rid15">15-19</a>]. Ideally, patients should be evaluated for a systemic agent that is different from that originally used for concurrent therapy. </p><p>Systemic regimens that incorporate checkpoint inhibitor immunotherapy are an appropriate treatment option for patients with advanced or metastatic disease previously treated with chemoradiotherapy. (See  <a class="medical medical_review" href="/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer", section on 'Previous systemic therapy for locoregional disease'</a>.)</p><p>The addition of immunotherapy to reirradiation in the treatment of locally recurrent disease requires further investigation. (See  <a class="medical medical_review" href="/d/html/3371.html" rel="external">"Methods to overcome radiation resistance in head and neck cancer", section on 'Checkpoint inhibitor immunotherapy'</a> and <a class="local">'Novel/targeted agents'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Treatment volume</span><span class="headingEndMark"> — </span>A thorough analysis of the initial treatment volumes and dose distributions relative to the location of the locoregional recurrence or second primary tumor should be made when reirradiation is considered. Determination of the dose received at the site of recurrence may demonstrate geographic tumor miss and is necessary for treatment planning since a geographic or marginal miss may not represent the same radioresistant disease as a true in-field recurrence, even with a disease-free interval of less than a year.</p><p>Reirradiation treatment volumes for patients treated with IMRT (typically with concurrent chemotherapy) are usually limited to a 1 to 2 cm margin around the gross tumor or the surgical site, with even smaller margins when tumors are near critical structures such as the skull base/brainstem, spinal cord, optic nerve, or optic chiasm [<a href="#rid16">16</a>]. This approach was validated in a retrospective review of 66 reirradiated patients, which demonstrated that 96 percent of locoregional recurrences following reirradiation occurred within the gross tumor volume and only 4 percent occurred in untreated regional sites [<a href="#rid20">20</a>]. The cumulative dose to the spinal cord from all courses of treatment is usually limited to 50 Gy, with the reirradiation dose to the spinal cord restricted to 10 percent of the prescribed reirradiation dose [<a href="#rid16">16,21</a>]. Treatment volumes for patients reirradiated with stereotactic body radiation therapy (SBRT) are often limited to small deposits of gross disease and a &lt;1 cm margin for patient setup uncertainty.</p><p class="headingAnchor" id="H5"><span class="h2">Dose</span><span class="headingEndMark"> — </span>When employing standard, non-SBRT dosing schemes, doses ≥50 Gy to the tumor are necessary to yield substantial response rates and delay disease recurrence [<a href="#rid22">22</a>]. Many investigators and cooperative groups use 60 Gy as a target reirradiation dose, delivered through various reirradiation protocols [<a href="#rid15">15,23</a>]. Some large analyses demonstrate that patients treated to a higher radiation dose have improved survival and tumor control outcomes [<a href="#rid14">14,24</a>]. There is no consensus regarding total dose or use of any particular dose fractionation scheme. For patients with gross disease, we typically prescribe 70 to 75 Gy, and for those treated following gross total resection, we prescribe 60 to 66 Gy. </p><p class="headingAnchor" id="H6"><span class="h2">Modality</span><span class="headingEndMark"> — </span>Three-dimensional conformal planning and advanced delivery techniques such as IMRT, brachytherapy, intraoperative radiation therapy (IORT), stereotactic radiosurgery, and SBRT have been used to deliver high doses to tumors while minimizing the radiation dose to surrounding normal structures. Proton therapy or carbon ion therapy may facilitate dose escalation and/or normal tissue sparing [<a href="#rid25">25</a>], but data on its efficacy and safety for recurrent head and neck cancer are limited [<a href="#rid25">25-31</a>]. (See  <a class="medical medical_review" href="/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer", section on 'Charged particle radiation'</a>.)</p><p>IMRT is the external beam radiotherapy technique usually employed for head and neck reirradiation. This is based on observational studies demonstrating encouraging two-year rates of overall survival (up to 58 percent) and locoregional control (up to 64 percent) [<a href="#rid32">32-34</a>]. In addition, SBRT (alone or in combination with chemotherapy) achieves one-year locoregional disease control in approximately one-half of retreated patients [<a href="#rid35">35,36</a>]. (See <a class="local">'External beam radiation therapy'</a> below and <a class="local">'Stereotactic body radiation therapy'</a> below.)</p><p>Investigations are ongoing to further evaluate the integration of newer radiation techniques for the use of reirradiation. (See  <a class="medical medical_review" href="/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer"</a>.) </p><p class="headingAnchor" id="H7"><span class="h2">Elective neck treatment</span><span class="headingEndMark"> — </span>In the case of local tumor recurrence, the need for elective irradiation to the grossly uninvolved cervical lymphatics is controversial [<a href="#rid15">15</a>]. In our practice, we do not routinely treat elective nodal regions since the primary pattern of recurrence following reirradiation is in the reirradiated site [<a href="#rid20">20</a>]. Larger radiation volumes also significantly increase the risk of severe late toxicity. </p><p>Some patients may be evaluated for elective neck irradiation if those nodal areas are outside of the previous high-dose radiation field, more often in cases of limited prior radiation and second primary tumors with a historic propensity for nodal metastases. However, this must be carefully considered as neck irradiation can significantly increase the risk of side effects. In a multi-institutional retrospective study of 505 patients, elective nodal radiation was associated with greater risks of acute toxicity and did not improve overall survival [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H8"><span class="h1">POSTOPERATIVE REIRRADIATION</span><span class="headingEndMark"> — </span>We suggest postoperative reirradiation for completely surgically resected patients with high-risk pathologic features [<a href="#rid15">15,16,37</a>]. We offer the same concurrent chemotherapy protocols that are used for unresectable recurrences. (See <a class="local">'Reirradiation with concurrent chemotherapy'</a> below.)</p><p>The addition of postoperative reirradiation to surgical salvage may improve upon the results of using surgery alone. Retrospective reviews and phase I/II trials established the feasibility of postoperative reirradiation and suggested promising outcomes [<a href="#rid38">38,39</a>]. The Groupe d'Etude des Tumours Tete et Cou (GETTEC) in conjunction with Groupe d'Oncologie Radiotherapie Tete et Cou (GORTEC) conducted a prospective, randomized trial to confirm these results [<a href="#rid40">40</a>]. After a macroscopic complete resection, 130 patients were randomized to reirradiation (60 Gy in 12 weeks) in combination with chemotherapy (<a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>) or no postoperative therapy. Postoperative reirradiation was associated with an improvement in progression-free survival (PFS; hazard ratio [HR] 1.6, 95% CI 1.1-2.4) but not overall survival.</p><p>Subsequently, many have focused attention on those patients at highest risk of second failure after surgical salvage: those who have undergone macroscopic complete resections but were found to have high risk pathologic features, including positive margins, perineural invasion, lymphovascular invasion, or extranodal extension. As examples, two nonrandomized trials reported a three-year overall survival of 44 percent with postoperative reirradiation alone and a four-year overall survival of 43 percent with postoperative reirradiation with concurrent chemotherapy in these high-risk patients; however, these results may reflect patient selection bias towards those with a more favorable prognosis [<a href="#rid41">41,42</a>]. </p><p>A systematic review of 16 studies with 919 patients, including 522 who underwent reirradiation, reported wide ranges of local control (21 to 100 percent), two-year overall survival (24 to 81 percent), severe mucositis and/or dysphagia/pharyngitis (11 to 52 percent), late fibrosis (2 to 44 percent), and pharynx dysfunction (2 to 70 percent). The authors concluded that, while interpretation of the data is limited due to the heterogeneity of the patients and treatment characteristics, postoperative reirradiation with highly conformal techniques to doses &gt;50 Gy should be considered for selected patients with high-risk features (such as extracapsular extension or residual disease) [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H9"><span class="h1">REIRRADIATION FOR UNRESECTABLE RECURRENCES</span><span class="headingEndMark"> — </span>Although retrospective reviews and phase I/II studies have demonstrated that reirradiation with or without concurrent chemotherapy is feasible and that some patients may achieve long-term survival, it is not clear that reirradiation, with its accompanying toxicity, is superior to either systemic therapy alone or best supportive care. </p><p>For appropriately selected patients, we suggest reirradiation with concurrent chemotherapy over systemic therapy or reirradiation alone. The data supporting this approach are derived from small, nonrandomized studies. Randomized trials designed to address this question were terminated because of poor accrual [<a href="#rid10">10</a>]. Differences in patient populations due to selection bias influence outcomes and toxicity rates and limit comparisons between studies. As a general principle and when feasible, patients who have undergone previous concurrent chemoradiation should receive a different systemic agent than what was administered originally, given the high likelihood of resistance to the original cytotoxic drug.</p><p class="headingAnchor" id="H10"><span class="h2">Surgical debulking prior to reirradiation</span><span class="headingEndMark"> — </span>For patients with an unresectable recurrence, surgical debulking (ie, an incomplete R1 or R2 resection) may be offered to select patients to palliate tumor-related symptoms. In contrast, experts differ in their use of surgical debulking prior to reirradiation in patients who do not require palliation.</p><p>Surgical salvage is the standard of care for patients with resectable disease, but the role of debulking surgery prior to reirradiation is less clear. Surgical debulking prior to reirradiation may allow better sparing of normal tissues and better facilitate definitive doses of radiation therapy (RT). However, it is unclear whether debulking improves disease control and overall survival. </p><p>Retrospective data suggest that, even in patients with an unresectable recurrence, surgical debulking prior to reirradiation improves disease control and/or survival [<a href="#rid22">22,38,44</a>]. In contrast, a prospective, nonrandomized phase II trial failed to show a difference in survival with the addition of surgery [<a href="#rid45">45</a>]. In this study, 35 patients with recurrent or second primary head and neck cancer were treated with two cycles of chemotherapy followed by local therapy (either surgery followed by chemotherapy [<a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> plus <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>] and reirradiation or chemotherapy and reirradiation alone). Surgical candidacy was determined prior to the initial chemotherapy. In the final analysis of this study, survival was similar between those who underwent surgery (including incomplete debulking procedures) and those who did not [<a href="#rid45">45</a>].</p><p>Debulking surgery can provide immediate palliation of symptoms. However, surgery may disfigure the patient, and it could delay or even preclude the start of planned reirradiation (with or without chemotherapy) due to surgical complications. </p><p>Debulking surgery may also delay or preclude the more appropriate use of reirradiation due to postoperative complications. Therefore, clinicians offering this approach must select patients carefully, inform them of the limited data supporting this approach, and discuss the potential toxicities of multimodality therapy. </p><p class="headingAnchor" id="H11"><span class="h2">Reirradiation alone</span><span class="headingEndMark"> — </span>Depending on the population examined, reasonable survival rates have been reported with primary reirradiation without chemotherapy [<a href="#rid46">46-57</a>]. However, many of these trials were done before concomitant chemotherapy and RT became the standard treatment for advanced head and neck cancer. More commonly, however, when RT to the head and neck is employed, chemotherapy is given concurrently to overcome radioresistance and improve outcomes.</p><p class="headingAnchor" id="H12"><span class="h3">External beam radiation therapy</span><span class="headingEndMark"> — </span>Intensity-modulated radiation therapy (IMRT) is the external beam radiotherapy (EBRT) technique usually employed for reirradiation of recurrent head and neck cancer, as this approach improves local control with less treatment-related toxicity [<a href="#rid32">32,33,44</a>]. With EBRT alone, three-year overall survival rates are approximately between 13 and 22 percent [<a href="#rid47">47,57</a>]. (See <a class="local">'Modality'</a> above.)</p><p class="headingAnchor" id="H13"><span class="h3">Brachytherapy</span><span class="headingEndMark"> — </span>Interstitial brachytherapy alone or in combination with EBRT has yielded five-year locoregional control rates as high as 50 to 70 percent and five-year overall survival of 11 to 30 percent [<a href="#rid51">51,53,54,58</a>]. Sites amenable to this approach include the oral cavity and oropharynx.</p><p>Brachytherapy is a reasonable treatment option for patients with recurrent disease at centers with appropriate expertise. As an example, one center has used interstitial brachytherapy for recurrent head and neck cancer since the mid-1970s, initially with low-dose-rate brachytherapy and then transitioning to high-dose-rate brachytherapy [<a href="#rid54">54</a>]. In the most recent report of their experience with high-dose-rate brachytherapy delivered at doses of 18 to 48 Gy in 3 to 4 Gy, twice daily fractions, the two-year disease-specific and overall survival rates were 45 and 37 percent, respectively. (See  <a class="medical medical_review" href="/d/html/3406.html" rel="external">"General principles of radiation therapy for head and neck cancer"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Intraoperative radiation therapy</span><span class="headingEndMark"> — </span>Intraoperative radiation therapy (IORT; with electrons or high-dose-rate brachytherapy) combined with debulking surgery allows visualization of the target and avoidance of uninvolved structures. Two-year local control rates and overall survival of 60 and 55 percent have been reported [<a href="#rid55">55,59</a>]. While local control rates with IORT are acceptable with completely resected disease, high local failure rates may preclude its use for gross residual disease.</p><p class="headingAnchor" id="H24952346"><span class="h3">Stereotactic body radiation therapy</span><span class="headingEndMark"> — </span>Stereotactic body radiation therapy (SBRT), which uses anatomic references (ie, skull or spine), surgically placed fiducials, external markers, and/or a rigid stereotactic frame to more accurately target radiation treatment, is emerging as an option for reirradiation of head and neck cancer [<a href="#rid60">60</a>]. Case series have reported good local control and toxicity comparable to conformal techniques.</p><p>SBRT allows for the delivery of "ablative doses" of hypofractioned radiation (ie, high dose per fraction) generally in one to five treatments by utilizing technology to optimize targeting accuracy, which facilitates dose escalation and normal tissue sparing [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Stereotactic radiation therapy techniques'</a>.)</p><p>SBRT should only be offered to those patients with relatively low-volume recurrent disease confined to a discrete focus or foci where SBRT can be administered in a relatively safe manner. When SBRT is used to treat head and neck cancer recurrences, the recurrence must be well visualized on imaging to ensure accurate delivery of ablative doses of radiation. In a retrospective study of 85 patients treated with head and neck SBRT reirradiation (70 percent of whom also received induction, concurrent, and/or adjuvant systemic therapy), the two-year overall survival and local control rates were 24 and 28 percent, respectively [<a href="#rid62">62</a>]. </p><p>A large, single-institution report found that patients with an isolated neck recurrence had the lowest risk of late toxicity, while those with laryngeal and hypopharyngeal cancer had a 50 percent risk of grade 3 or greater toxicity following SBRT, significantly higher than at other sites (6 to 20 percent). Interestingly, SBRT dose &gt;44 Gy was independently associated with both acute and late toxicity, while the RT treatment platform was not [<a href="#rid63">63</a>]. In another study, concurrent systemic therapy was associated with greater regional and distant control, and higher grade ≥3 toxicity [<a href="#rid64">64</a>]. While phase I data exist, the optimal dose and fractionation schedule of SBRT for head and neck reirradiation to maximize efficacy and minimize toxicity risk is unknown [<a href="#rid65">65</a>].</p><p>A pooled analysis conducted by the American Association of Physicists in Medicine Hypofractionated Treatment Effects in the Clinic (HyTEC) working group analyzed 300 cases in eight publications; from their data modeling, 35 to 45 Gy (in five fractions) was associated with greater tumor control probability and overall survival compared with doses &lt;30 Gy [<a href="#rid66">66</a>].</p><p>There do not appear to be survival differences between head and neck reirradiation with SBRT and conventionally fractionated IMRT, albeit based upon retrospective data [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Reirradiation with concurrent chemotherapy</span><span class="headingEndMark"> — </span>Many institutions have reported relatively promising results from single-institution phase I/II trials of reirradiation with concurrent chemotherapy [<a href="#rid34">34</a>]. These results have been repeated in the multi-institutional cooperative group setting, and in one study, the benefit of reirradiation with concurrent chemotherapy over observation was demonstrated [<a href="#rid40">40,67,68</a>].</p><p>Until additional data are published, we favor reirradiation with concurrent chemotherapy over either chemotherapy alone or RT alone. Although there is no standard concurrent chemotherapy regimen for use with reirradiation, patients should be treated with established regimens, which are discussed below, or encouraged to participate in clinical trials. The chemotherapy regimen should avoid drugs to which the patient was previously exposed.</p><p>Patient selection is critical as these regimens are associated with considerable toxicity. Patient selection is based upon tumor characteristics as well as an assessment of the patients' prognosis and their ability and willingness to tolerate the anticipated toxicity of these regimens. (See <a class="local">'Toxicity'</a> below and <a class="local">'Prognostic factors'</a> below.)</p><p class="headingAnchor" id="H16"><span class="h3">FHX/FHX2 regimens</span><span class="headingEndMark"> — </span>One of the best studied combinations is concomitant <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) and <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> with reirradiation (FHX) [<a href="#rid22">22,23,40,67</a>]. Investigators at the University of Chicago have reported on 45 patients enrolled in four prospective phase I-II trials [<a href="#rid69">69</a>]. <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> was added to the chemotherapy regimen in three of the four trials. Five-year locoregional control, PFS, and overall survival were 14, 15, and 20 percent, respectively.</p><p>For the original FHX protocol, RT was delivered on alternating weeks (five-day treatment cycle followed by a nine-day break). The regimen was modified in subsequent studies to twice-daily, week-on/week-off RT (FHX2).</p><p>Radiation Therapy Oncology Group (RTOG) 9610, which included 81 patients, tested FHX2, but with a lower FU dose, in the cooperative group setting. The two-year and five-year survival rates were 15 and 4 percent, respectively [<a href="#rid67">67,70</a>].</p><p>In a pooled analysis of 115 patients treated with FHX/FHX2, FHX plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, TFHX2 (including <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>), and TFGX2 (including paclitaxel and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>) regimens at the University of Chicago, the three-year locoregional control rates, PFS, and overall survival were 51, 33, and 22 percent, respectively [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H19"><span class="h3">Platinum combinations</span><span class="headingEndMark"> — </span>Promising single institution results with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> concurrent with hyperfractionated RT have been replicated in a cooperative group phase II trial, RTOG 9911 [<a href="#rid68">68,71</a>]. Hematopoietic growth factor, G-CSF, was added to the protocol to reduce the acute toxicity and treatment delays experienced during the initial studies. With 99 patients treated and 74 percent completing therapy, two-year PFS and overall survival rates were 16 and 26 percent, respectively. These survival rates are superior to the results from RTOG 9610 and exceed those generally seen with chemotherapy alone. However, they do come at the cost of apparent increased toxicity, and caution is warranted in comparing nonrandomized trials.</p><p>This regimen of <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> was selected as the concurrent chemotherapy for the reirradiation arm in RTOG 0421; however, this trial has closed due to poor accrual [<a href="#rid72">72</a>].</p><p>Other promising platinum regimens include <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>/<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid73">73</a>], <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>/<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid74">74</a>], cisplatin/FU [<a href="#rid75">75</a>], and carboplatin/pemetrexed, which have been used in combination with induction chemotherapy [<a href="#rid76">76</a>]. Cisplatin alone concurrent with reirradiation is also used [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Induction chemotherapy</span><span class="headingEndMark"> — </span>Induction chemotherapy followed by surgery and reirradiation has been investigated based upon results in the first-line therapy of advanced head and neck cancer. (See  <a class="medical medical_review" href="/d/html/3392.html" rel="external">"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy", section on 'Induction chemotherapy'</a>.)</p><p>Induction with <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, followed by resection in patients amenable to surgery, and then reirradiation with concurrent <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and pemetrexed yielded a one-year survival rate of 42 percent [<a href="#rid76">76</a>]. Poor response to induction chemotherapy predicted worse survival, a finding that may be used in subsequent studies to select patients for reirradiation.</p><p class="headingAnchor" id="H21"><span class="h2">Novel/targeted agents</span><span class="headingEndMark"> — </span>New agents, alone or in combination with cytotoxic chemotherapy, are being added to reirradiation as a means of overcoming radioresistance. </p><p>Treatments that have been investigated include checkpoint inhibitor immunotherapy (eg, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> [<a href="#rid78">78</a>], <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> plus SBRT [<a href="#rid79">79</a>]); single-agent <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> with either SBRT [<a href="#rid36">36,80</a>] or conventionally fractionated reirradiation [<a href="#rid81">81-83</a>]; cetuximab plus <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid84">84</a>]; and intratumoral injection of TNFerade (a replication defective adenoviral vector that carries a human tumor necrosis factor [TNF] gene linked to the radiation inducible promoter, early growth response protein [EGR-1]) in conjunction with FHX2 [<a href="#rid85">85</a>]. </p><p>Other targeted agents have either not demonstrated efficacy, such as antiangiogenesis agents (ie, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>) [<a href="#rid86">86,87</a>] or are not feasible due to toxicity, such as <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Isolated neck recurrence</span><span class="headingEndMark"> — </span>Surgical salvage of an isolated neck recurrence is a standard curative-intent approach, and specific surgical issues that pertain to the irradiated neck are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3373.html" rel="external">"Treatment of locally recurrent squamous cell carcinoma of the head and neck"</a>.)</p><p>Interstitial brachytherapy and IORT are ideal for treatment of an isolated neck recurrence since the radiation dose can be selectively delivered to the neck. However, scant data exist. In one series of 22 patients treated with salvage neck dissection and low dose rate brachytherapy, the two-year regional control and overall survival rates were 67 and 57 percent [<a href="#rid89">89</a>]. Others, after appreciating that reirradiation of the neck with brachytherapy resulted in necrosis and fibrosis in 42 percent of patients, modified the technique to include skin resurfacing with a myocutaneous graft. Subsequently, this complication rate was lowered to 11 percent [<a href="#rid90">90</a>].</p><p class="headingAnchor" id="H23"><span class="h1">PALLIATIVE REIRRADIATION</span><span class="headingEndMark"> — </span>Although data are limited, palliative irradiation is an option for patients whose tumor is significantly impacting quality of life and who are not candidates for an aggressive course of reirradiation. In general, tumor shrinkage with palliative reirradiation is expected to be greater than the response to chemotherapy. Lower doses and larger fraction sizes are delivered to patients receiving palliative reirradiation. The lower dose should result in a lower risk of acute toxicity, and the increased risk of late complications with larger fraction sizes is generally not relevant.</p><p>The "Quad Shot" approach to palliative radiation therapy (RT) delivers short, cyclical courses to maximize clinical response and minimize toxicity [<a href="#rid91">91</a>]. Each cycle consists of twice-daily hypofractionated RT administered over two days in four-week intervals for a total of two or more cycles depending on treatment response. This approach allows mucosal stem cells to repopulate before the next cycle [<a href="#rid91">91</a>]. </p><p>While the best data regarding the Quad Shot approach come from an uncontrolled prospective trial in patients without prior RT exposure [<a href="#rid91">91</a>], we offer this approach to patients with prior RT exposure who are not candidates for more aggressive treatment, as the limited observational data in the setting of reirradiation are promising [<a href="#rid92">92,93</a>]. </p><p>In two retrospective studies including a total of 101 patients with incurable recurrent or metastatic head and neck cancer treated with the Quad Shot approach (53 patients with prior RT), responses were seen in 65 to 73 percent, and there was a low rate of grade ≥3 toxicities [<a href="#rid92">92-94</a>]. Of note, previous RT exposure did not appear to be negatively predictive of palliative response, as responses were seen just as frequently in those with prior RT exposure [<a href="#rid93">93</a>]. </p><p>Patients with multifocal locoregional recurrences, metastatic disease, and short interval between initial treatment and recurrence have such a limited survival that the likelihood of severe treatment-related toxicity usually outweighs any palliative benefit from reirradiation [<a href="#rid47">47,94,95</a>]. Systemic therapy for metastatic and recurrent head and neck cancer is discussed separately. (See  <a class="medical medical_review" href="/d/html/3364.html" rel="external">"Treatment of metastatic and recurrent head and neck cancer"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span>Reirradiation is a treatment option for some patients, but toxicity is a very important consideration [<a href="#rid96">96</a>]. Acute and long-term complications, including treatment-related fatalities from bleeding, tissue necrosis, and infection, are substantial.</p><p>Treatment-related fatalities with irradiation approach 10 percent, and the incidence of acute and late grade ≥3 toxicity is up to 50 percent [<a href="#rid67">67,68,97</a>], although the true risk of severe toxicities is likely higher. As such, it is critical to select patients judiciously and provide robust supportive care during and after therapy. Nomograms are available that can predict severe late toxicity after reirradiation, using patient, disease, and treatment-related factors [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer"</a> and  <a class="medical medical_review" href="/d/html/3365.html" rel="external">"Management of late complications of head and neck cancer and its treatment"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Reirradiation alone</span><span class="headingEndMark"> — </span>Even with reirradiation alone (ie, without concurrent chemotherapy), toxicity is high. Acute complications in this setting are mainly mucositis and pain. Reirradiation may also result in multiple severe toxicities within the same patient. A series of 41 patients, 78 percent treated with intensity-modulated radiation therapy (IMRT), reported radiation-related toxicity and disease-related problems occurring in 81 percent of patients with grade 3 or 4 toxicity in 68 percent [<a href="#rid47">47</a>].</p><p>The risk of long-term toxicity from reirradiation is high but can be limited with reductions in the size of the target volume with conformal delivery techniques and by adopting split-course schedules with smaller fraction sizes. With these modifications, the incidence of radiation necrosis is generally less than 25 percent [<a href="#rid37">37</a>]. Severe late complications, each with an incidence as high as 5 percent, include mucosal ulceration/necrosis, neck fibrosis, trismus, orocutaneous fistula, carotid blow out, hemorrhage, chondronecrosis/osteoradionecrosis, feeding tube dependency, and death [<a href="#rid37">37</a>]. </p><p>In a pooled analysis of 39 studies with approximately 3800 patients undergoing head and neck reirradiation, the rate of any grade ≥3 late toxicity was 29 percent; the most common toxicities included radionecrosis, dysphagia requiring feeding tube placement, and trismus. Additionally, the estimated rate of fatal carotid blowout was 4 percent [<a href="#rid96">96</a>]. (See <a class="local">'Carotid artery injury'</a> below.)</p><p>When stereotactic body radiation therapy (SBRT) is used in the reirradiation setting, grade 3 or greater late toxicity is more common when the larynx/hypopharynx sites are targeted. Additionally, these later effects are more common after doses &gt;44 Gy in five fractions [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Reirradiation with chemotherapy</span><span class="headingEndMark"> — </span>The addition of chemotherapy to radiation therapy has added to the toxicity in most reports. Evidence suggests that acute toxicity with reirradiation and concurrent chemotherapy is similar to the toxicity associated with an initial course of concurrent chemoradiation [<a href="#rid40">40,67,68,70</a>].</p><p>The following two trials illustrate the scope and high rates of toxicity with reirradiation and concurrent chemotherapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation Therapy Oncology Group (RTOG) 9610</strong> – Acute toxicity, occurring within 90 days of the start of treatment, resulted in death in 6 of 79 treated patients (8 percent), two due to hemorrhage and four due to neutropenia [<a href="#rid67">67</a>]. Grade 3 to 5 overall, nonhematologic, and hematologic acute toxicity occurred in 63, 49, and 37 percent of patients, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RTOG 9911</strong> – The total treatment-related fatality rate was 11 percent, with 5 percent occurring in the acute period [<a href="#rid68">68</a>]. Cause of death included neutropenic sepsis, dehydration and shock, pneumonitis, and stroke. Grade ≥3 overall, nonhematologic, and hematologic acute toxicity occurred in 78, 77, and 45 percent of patients, respectively. Of these, grade ≥3 neutropenia occurred in 24 percent, infection/neutropenic fever in 15 percent, mucositis in 14 percent, and GI toxicity in 48 percent.</p><p></p><p>Differentiating the toxicity of reirradiation from that of previous treatment can be difficult. In RTOG 9610, the cumulative incidence of grade 3 or greater toxicity in patients surviving more than one year was 12 percent [<a href="#rid67">67,70</a>]. In RTOG 9911, an estimated 85 and 32 percent experienced overall and nonhematologic grade 3 to 5 toxicity over the first two years of follow-up. There were three late fatalities in RTOG 9911, two due to carotid hemorrhages and one from oral-cutaneous fistula and soft tissue necrosis. Late toxicities reported in these trials and others include cervical fibrosis (31 to 48 percent), osteoradionecrosis (5 to 16 percent), trismus (9 to 24 percent), and carotid hemorrhage (2 to 5 percent) [<a href="#rid16">16</a>]. Although long-term spinal cord and brainstem toxicity has been rare, this may be due to selection of patients with tumors not in close proximity to the spinal cord [<a href="#rid22">22,67,68,70</a>].</p><p class="headingAnchor" id="H28"><span class="h2">Carotid artery injury</span><span class="headingEndMark"> — </span>Carotid artery hemorrhage and rupture are particularly dreaded complications of reirradiation [<a href="#rid37">37,98</a>]. Patients at particular risk for this complication include those with long-term tracheostomies, active infections, pharyngocutaneous fistulas, poor wound healing, prior neck dissection, and tumor adherent to the carotid fascia [<a href="#rid99">99</a>]. </p><p>In a literature review of 27 series that included 1554 patients managed with reirradiation, the rate of carotid blowout was 2.6 percent and appeared to be higher in patients treated with accelerated fractionation regimens [<a href="#rid100">100</a>]. In another study of 412 patients, the rate of carotid bleeding was 1.2 percent with a median time between courses of 2.4 years (range 0.3 to 11.7 years) among these patients [<a href="#rid13">13,101</a>]. </p><p>One report (Hypofractionated Treatment Effects in the Clinic [HyTEC]) modeled carotid events after reirradiation with SBRT. In order to minimize risks of carotid or other bleeding events, this report recommended delivery of treatment on nonconsecutive days, restricting the reirradiated major vessel volume exceeding 20 to 30 Gy to be as small as possible, and considering alternative (ie, non-SBRT) RT approaches when circumferential carotid radiation is unavoidable [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/d/html/3365.html" rel="external">"Management of late complications of head and neck cancer and its treatment", section on 'Carotid artery injury'</a>.)</p><p>Stabilization of the carotid, by means of a surgical flap reconstruction or an endovascular stent, prior to reirradiation in patients at risk has been proposed but is untested [<a href="#rid8">8,103</a>]. </p><p class="headingAnchor" id="H29"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>Several factors have been identified as prognostic of both locoregional control and survival for patients undergoing reirradiation for recurrent and/or second primary tumors:</p><p class="bulletIndent1"><span class="glyph">●</span>Second primary tumors fare better than recurrent tumors [<a href="#rid46">46,70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical debulking of the recurrent tumor is associated with improved outcomes [<a href="#rid14">14,22,33,38,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive recurrent disease is associated with worse outcomes [<a href="#rid11">11,47,95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A longer time interval to recurrence affords a better prognosis [<a href="#rid11">11,14,16,67,104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laryngeal and nasopharyngeal tumors have a more favorable prognosis as compared with other sites [<a href="#rid33">33,56,105-107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrences in the neck fare poorly as compared with primary site recurrences [<a href="#rid77">77,101,108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher doses of radiation therapy yield better outcomes [<a href="#rid11">11,13,14,22,33,38,75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multi-agent chemotherapy has been associated not only with improved survival but also decreased distant metastases [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical comorbidities and laryngeal/pharyngeal organ dysfunction have a markedly negative impact on survival [<a href="#rid101">101,109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior treatment with concomitant chemotherapy and radiation has a worse survival [<a href="#rid14">14</a>].</p><p></p><p>In a recursive partitioning analysis of 412 patients, the interval between courses (&gt;2 versus ≤2 years), resection of recurrence (among those with &gt;2 years between courses), and organ dysfunction (among those with ≤2 years between courses) allowed grouping of patients into three groups with two-year overall survival rates of 62, 40, and 17 percent [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H1235752532"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/128559.html" rel="external">"Society guideline links: Head and neck cancer"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approaches</strong> – Patients presenting with recurrent head and neck cancer in a previously irradiated field present a therapeutic challenge. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Salvage surgery, if feasible, represents the preferred treatment option.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reirradiation, with or without chemotherapy, has become an accepted alternative to chemotherapy or supportive care and may offer long-term survival for selected patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection </strong>– Because of the toxicity associated with reirradiation for recurrent head and neck cancer or a second primary tumor, patient selection is critical. Factors to be considered include the dose of prior radiation therapy (RT) and the radiation fields, the time since prior treatment, the extent and location of recurrent tumor, and the overall patient condition and comorbidities. (See <a class="local">'Patient selection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resected disease with high-risk pathologic features </strong>– For patients with high-risk pathologic features after complete surgical resection of a recurrence or second primary, we suggest postoperative reirradiation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Postoperative Reirradiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resected disease without high-risk pathologic features </strong>– For patients without high-risk features after complete surgical resection of a recurrence or second primary, we do not suggest postoperative reirradiation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Postoperative Reirradiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unresectable, locally recurrent disease </strong>– For selected patients with unresectable, locally recurrent head and neck cancer without distant metastases, we suggest reirradiation with concurrent chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Stereotactic body radiation therapy (SBRT) is an emerging treatment option. (See <a class="local">'Reirradiation with concurrent chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical debulking (ie, an incomplete R1 or R2 resection) may be offered to select patients to palliate tumor-related symptoms. Experts differ in their use of surgical debulking prior to reirradiation in patients who do not require palliation. (See <a class="local">'Surgical debulking prior to reirradiation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no standard concurrent chemotherapy regimen. Patients should be treated with established regimens (eg, the FHX regimen [<a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> with reirradiation] or a paclitaxel-platinum combination) or encouraged to participate in clinical trials. (See <a class="local">'Reirradiation with concurrent chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palliative reirradiation </strong>– For some patients who are not candidates for curative-intent treatment but who have symptomatic local disease or are likely to experience symptoms from local progression, palliative reirradiation may provide symptom relief. (See <a class="local">'Palliative reirradiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity </strong>– The toxicity from reirradiation is considerable. Treatment-related fatalities approach 10 percent, and the incidence of acute and late grade ≥3 toxicity is up to 50 percent. As such, it is critical to select patients judiciously and provide robust supportive care during and after therapy. (See <a class="local">'Toxicity'</a> above and  <a class="medical medical_review" href="/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer"</a> and  <a class="medical medical_review" href="/d/html/3365.html" rel="external">"Management of late complications of head and neck cancer and its treatment"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bourhis J, Le Maître A, Baujat B, et al. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 2007; 19:188.</a></li><li><a class="nounderline abstract_t">Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15:1179.</a></li><li><a class="nounderline abstract_t">Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945.</a></li><li><a class="nounderline abstract_t">Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937.</a></li><li><a class="nounderline abstract_t">Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091.</a></li><li><a class="nounderline abstract_t">Hall SF, Groome PA, Irish J, O'Sullivan B. The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope 2008; 118:1362.</a></li><li><a class="nounderline abstract_t">Kao J, Garofalo MC, Milano MT, et al. Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. Cancer Treat Rev 2003; 29:21.</a></li><li><a class="nounderline abstract_t">Chmura SJ, Milano MT, Haraf DJ. Reirradiation of recurrent head and neck cancers with curative intent. Semin Oncol 2004; 31:816.</a></li><li><a class="nounderline abstract_t">McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011; 80:1292.</a></li><li><a class="nounderline abstract_t">Patel PR, Salama JK. Reirradiation for recurrent head and neck cancer. Expert Rev Anticancer Ther 2012; 12:1177.</a></li><li><a class="nounderline abstract_t">Chen AM, Phillips TL, Lee NY. Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? Int J Radiat Oncol Biol Phys 2011; 81:1211.</a></li><li><a class="nounderline abstract_t">Strojan P, Corry J, Eisbruch A, et al. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck 2015; 37:134.</a></li><li><a class="nounderline abstract_t">Vargo JA, Ward MC, Caudell JJ, et al. A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2018; 100:595.</a></li><li><a class="nounderline abstract_t">Choe KS, Haraf DJ, Solanki A, et al. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 2011; 117:4671.</a></li><li><a class="nounderline abstract_t">Langendijk JA, Bourhis J. Reirradiation in squamous cell head and neck cancer: recent developments and future directions. Curr Opin Oncol 2007; 19:202.</a></li><li><a class="nounderline abstract_t">Salama JK, Vokes EE. Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol 2008; 35:251.</a></li><li><a class="nounderline abstract_t">Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol 2007; 4:86.</a></li><li><a class="nounderline abstract_t">Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007; 4:172.</a></li><li><a class="nounderline abstract_t">Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006; 16:2.</a></li><li><a class="nounderline abstract_t">Popovtzer A, Gluck I, Chepeha DB, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 2009; 74:1342.</a></li><li><a class="nounderline abstract_t">Nieder C, Grosu AL, Andratschke NH, Molls M. Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Radiat Oncol Biol Phys 2005; 61:851.</a></li><li><a class="nounderline abstract_t">Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006; 64:382.</a></li><li><a class="nounderline abstract_t">Spencer SA, Wheeler RH, Peters GE, et al. Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol 1999; 22:1.</a></li><li><a class="nounderline abstract_t">Caudell JJ, Ward MC, Riaz N, et al. Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. Int J Radiat Oncol Biol Phys 2018; 100:606.</a></li><li><a class="nounderline abstract_t">Eekers DBP, Roelofs E, Jelen U, et al. Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiother Oncol 2016; 121:387.</a></li><li><a class="nounderline abstract_t">McDonald MW, et al. Reirradiation of recurrent and second primary head and neck cancer with proton therapy. Int J Radiat Oncol Biol Phys 2016; 4:808.</a></li><li><a class="nounderline abstract_t">Romesser PB, Cahlon O, Scher ED, et al. Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes. Int J Radiat Oncol Biol Phys 2016; 95:386.</a></li><li><a class="nounderline abstract_t">Phan J, Sio TT, Nguyen TP, et al. Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys 2016; 96:30.</a></li><li><a class="nounderline abstract_t">Verma V, Rwigema JM, Malyapa RS, et al. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. Radiother Oncol 2017; 125:21.</a></li><li><a class="nounderline abstract_t">Lee A, Woods R, Mahfouz A, et al. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma. JAMA Netw Open 2023; 6:e2250607.</a></li><li><a class="nounderline abstract_t">Takahashi D, Demizu Y, Koto M, et al. Multicenter study of re-irradiation using carbon-ions for head and neck malignancies after photon radiotherapy. Cancer Med 2022; 11:3593.</a></li><li><a class="nounderline abstract_t">Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009; 73:399.</a></li><li><a class="nounderline abstract_t">Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 68:731.</a></li><li><a class="nounderline abstract_t">Lee J, Shin IS, Kim WC, et al. Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: Meta-analysis and systematic review. Head Neck 2020; 42:2473.</a></li><li><a class="nounderline abstract_t">Vargo JA, Wegner RE, Heron DE, et al. Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. Head Neck 2012; 34:1153.</a></li><li><a class="nounderline abstract_t">Vargo JA, Ferris RL, Ohr J, et al. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2015; 91:480.</a></li><li><a class="nounderline abstract_t">Kasperts N, Slotman B, Leemans CR, Langendijk JA. A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol 2005; 41:225.</a></li><li><a class="nounderline abstract_t">Milano MT, Vokes EE, Salama JK, et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys 2005; 61:1096.</a></li><li><a class="nounderline abstract_t">Martínez-Monge R, Alcalde J, Concejo C, et al. Perioperative high-dose-rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: Initial results of a Phase I/II reirradiation study. Brachytherapy 2006; 5:32.</a></li><li><a class="nounderline abstract_t">Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26:5518.</a></li><li><a class="nounderline abstract_t">Kasperts N, Slotman BJ, Leemans CR, et al. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer 2006; 106:1536.</a></li><li><a class="nounderline abstract_t">De Crevoisier R, Domenge C, Wibault P, et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 2001; 91:2071.</a></li><li><a class="nounderline abstract_t">Merlotti A, Mazzola R, Alterio D, et al. What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria. Crit Rev Oncol Hematol 2017; 111:20.</a></li><li><a class="nounderline abstract_t">Biagioli MC, Harvey M, Roman E, et al. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69:1067.</a></li><li><a class="nounderline abstract_t">Villaflor VM, Haraf D, Salama JK, et al. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol 2011; 22:2501.</a></li><li><a class="nounderline abstract_t">Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994; 29:687.</a></li><li><a class="nounderline abstract_t">Goldstein DP, Karnell LH, Yao M, et al. Outcomes following reirradiation of patients with head and neck cancer. Head Neck 2008; 30:765.</a></li><li><a class="nounderline abstract_t">Levendag PC, Meeuwis CA, Visser AG. Reirradiation of recurrent head and neck cancers: external and/or interstitial radiation therapy. Radiother Oncol 1992; 23:6.</a></li><li><a class="nounderline abstract_t">Langlois D, Hoffstetter S, Malissard L, et al. Salvage irradiation of oropharynx and mobile tongue about 192 iridium brachytherapy in Centre Alexis Vautrin. Int J Radiat Oncol Biol Phys 1988; 14:849.</a></li><li><a class="nounderline abstract_t">Peiffert D, Pernot M, Malissard L, et al. Salvage irradiation by brachytherapy of velotonsillar squamous cell carcinoma in a previously irradiated field: results in 73 cases. Int J Radiat Oncol Biol Phys 1994; 29:681.</a></li><li><a class="nounderline abstract_t">Grimard L, Esche B, Lamothe A, et al. Interstitial low-dose-rate brachytherapy in the treatment of recurrent head and neck malignancies. Head Neck 2006; 28:888.</a></li><li><a class="nounderline abstract_t">Mazeron JJ, Langlois D, Glaubiger D, et al. Salvage irradiation of oropharyngeal cancers using iridium 192 wire implants: 5-year results of 70 cases. Int J Radiat Oncol Biol Phys 1987; 13:957.</a></li><li><a class="nounderline abstract_t">Puthawala A, Nisar Syed AM, Gamie S, et al. Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results. Int J Radiat Oncol Biol Phys 2001; 51:354.</a></li><li><a class="nounderline abstract_t">Hepel JT, Syed AM, Puthawala A, et al. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005; 62:1444.</a></li><li><a class="nounderline abstract_t">Perry DJ, Chan K, Wolden S, et al. High-dose-rate intraoperative radiation therapy for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010; 76:1140.</a></li><li><a class="nounderline abstract_t">Dawson LA, Myers LL, Bradford CR, et al. Conformal re-irradiation of recurrent and new primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:377.</a></li><li><a class="nounderline abstract_t">Langendijk JA, Kasperts N, Leemans CR, et al. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol 2006; 78:306.</a></li><li><a class="nounderline abstract_t">Nag S, Cano ER, Demanes DJ, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2001; 50:1190.</a></li><li><a class="nounderline abstract_t">Rate WR, Garrett P, Hamaker R, et al. Intraoperative radiation therapy for recurrent head and neck cancer. Cancer 1991; 67:2738.</a></li><li><a class="nounderline abstract_t">Rwigema JC, Heron DE, Ferris RL, et al. Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am J Clin Oncol 2010; 33:286.</a></li><li><a class="nounderline abstract_t">Baliga S, Kabarriti R, Ohri N, et al. Stereotactic body radiotherapy for recurrent head and neck cancer: A critical review. Head Neck 2017; 39:595.</a></li><li><a class="nounderline abstract_t">Kress MA, Sen N, Unger KR, et al. Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series. Head Neck 2015; 37:1403.</a></li><li><a class="nounderline abstract_t">Ling DC, Vargo JA, Ferris RL, et al. Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2016; 95:973.</a></li><li><a class="nounderline abstract_t">Diao K, Nguyen TP, Moreno AC, et al. Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. Head Neck 2021; 43:3331.</a></li><li><a class="nounderline abstract_t">Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009; 75:1493.</a></li><li><a class="nounderline abstract_t">Vargo JA, Moiseenko V, Grimm J, et al. Head and Neck Tumor Control Probability: Radiation Dose-Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group. Int J Radiat Oncol Biol Phys 2021; 110:137.</a></li><li><a class="nounderline abstract_t">Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008; 30:281.</a></li><li><a class="nounderline abstract_t">Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007; 25:4800.</a></li><li><a class="nounderline abstract_t">Haraf DJ, Weichselbaum RR, Vokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol 1996; 7:913.</a></li><li><a class="nounderline abstract_t">Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001; 51:1299.</a></li><li><a class="nounderline abstract_t">Kramer NM, Horwitz EM, Cheng J, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 2005; 27:406.</a></li><li class="breakAll">http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0421 (Accessed on August 22, 2011).</li><li class="breakAll">Marwaha A, Choong NW, Firat S, et al. Clinical efficacy and tolerability of continuous course reirradiation with concurrent weekly carboplatin-paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN) (abstract #5518). J Clin Oncol 2010; 28:7s. </li><li><a class="nounderline abstract_t">Hehr T, Classen J, Belka C, et al. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys 2005; 61:1423.</a></li><li><a class="nounderline abstract_t">Machtay M, Rosenthal DI, Chalian AA, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59:72.</a></li><li class="breakAll">Villaflor VM, Cohen EE, Haraf D, et al. Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck cancer patients. J Clin Oncol 2008.</li><li><a class="nounderline abstract_t">Mabanta SR, Mendenhall WM, Stringer SP, Cassisi NJ. Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes. Head Neck 1999; 21:591.</a></li><li><a class="nounderline abstract_t">Altay-Langguth A, Balermpas P, Brandts C, et al. Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. Clin Transl Radiat Oncol 2021; 28:71.</a></li><li><a class="nounderline abstract_t">Wong S, Torres-Saavedra P, Le QT, et al. Safety of reRT with SBRT plus concurrent and adjuvant pembrolizumab in patients with recurrent or new second primary head and neck squamous cell cancer in a previously irradiated field: RTOG 3507 Foundation (KEYSTROKE). Int J Radiat Oncol Biol Phys 2020; 106.</a></li><li><a class="nounderline abstract_t">Lartigau EF, Tresch E, Thariat J, et al. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol 2013; 109:281.</a></li><li><a class="nounderline abstract_t">Balermpas P, Keller C, Hambek M, et al. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. Int J Radiat Oncol Biol Phys 2012; 83:e377.</a></li><li><a class="nounderline abstract_t">Tao Y, Faivre L, Laprie A, et al. Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab. Radiother Oncol 2018; 128:467.</a></li><li><a class="nounderline abstract_t">Hecht M, Hahn D, Wolber P, et al. A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Awan MJ, Nedzi L, Wang D, et al. Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck. Ann Oncol 2018; 29:998.</a></li><li><a class="nounderline abstract_t">Seiwert TY, Darga T, Haraf D, et al. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol 2013; 24:769.</a></li><li><a class="nounderline abstract_t">Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9:1957.</a></li><li><a class="nounderline abstract_t">Salama JK, Haraf DJ, Stenson KM, et al. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol 2011; 22:2304.</a></li><li><a class="nounderline abstract_t">Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 63:1400.</a></li><li><a class="nounderline abstract_t">Kupferman ME, Morrison WH, Santillan AA, et al. The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. Cancer 2007; 109:2052.</a></li><li><a class="nounderline abstract_t">Cornes PG, Cox HJ, Rhys-Evans PR, et al. Salvage treatment for inoperable neck nodes in head and neck cancer using combined iridium-192 brachytherapy and surgical reconstruction. Br J Surg 1996; 83:1620.</a></li><li><a class="nounderline abstract_t">Corry J, Peters LJ, Costa ID, et al. The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol 2005; 77:137.</a></li><li><a class="nounderline abstract_t">Ma J, Lok BH, Zong J, et al. Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. Int J Part Ther 2018; 4:10.</a></li><li><a class="nounderline abstract_t">Lok BH, Jiang G, Gutiontov S, et al. Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol 2015; 51:957.</a></li><li><a class="nounderline abstract_t">Fan D, Kang JJ, Fan M, et al. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. Oral Oncol 2020; 104:104641.</a></li><li><a class="nounderline abstract_t">Mendenhall WM, Mendenhall CM, Malyapa RS, et al. Re-irradiation of head and neck carcinoma. Am J Clin Oncol 2008; 31:393.</a></li><li><a class="nounderline abstract_t">Dionisi F, Fiorica F, D'Angelo E, et al. Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review. Oral Oncol 2019; 98:35.</a></li><li><a class="nounderline abstract_t">Ward MC, Lee NY, Caudell JJ, et al. A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck. Oral Oncol 2019; 90:80.</a></li><li><a class="nounderline abstract_t">Alterio D, Turturici I, Volpe S, et al. Carotid blowout syndrome after reirradiation for head and neck malignancies: a comprehensive systematic review for a pragmatic multidisciplinary approach. Crit Rev Oncol Hematol 2020; 155:103088.</a></li><li><a class="nounderline abstract_t">Upile T, Triaridis S, Kirkland P, et al. The management of carotid artery rupture. Eur Arch Otorhinolaryngol 2005; 262:555.</a></li><li><a class="nounderline abstract_t">McDonald MW, Moore MG, Johnstone PA. Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys 2012; 82:1083.</a></li><li><a class="nounderline abstract_t">Ward MC, Riaz N, Caudell JJ, et al. Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. Int J Radiat Oncol Biol Phys 2018; 100:586.</a></li><li><a class="nounderline abstract_t">Grimm J, Vargo JA, Mavroidis P, et al. Initial Data Pooling for Radiation Dose-Volume Tolerance for Carotid Artery Blowout and Other Bleeding Events in Hypofractionated Head and Neck Retreatments. Int J Radiat Oncol Biol Phys 2021; 110:147.</a></li><li><a class="nounderline abstract_t">Bates MC, Shamsham FM. Endovascular management of impending carotid rupture in a patient with advanced head and neck cancer. J Endovasc Ther 2003; 10:54.</a></li><li><a class="nounderline abstract_t">Kowalski LP. Results of salvage treatment of the neck in patients with oral cancer. Arch Otolaryngol Head Neck Surg 2002; 128:58.</a></li><li><a class="nounderline abstract_t">Wang CC. Re-irradiation of recurrent nasopharyngeal carcinoma--treatment techniques and results. Int J Radiat Oncol Biol Phys 1987; 13:953.</a></li><li><a class="nounderline abstract_t">Wang CC, McIntyre J. Re-irradiation of laryngeal carcinoma--techniques and results. Int J Radiat Oncol Biol Phys 1993; 26:783.</a></li><li><a class="nounderline abstract_t">Orlandi E, Bonomo P, Ferella L, et al. Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO-Head and Neck working group. Head Neck 2019; 41:3684.</a></li><li><a class="nounderline abstract_t">Emami B, Bignardi M, Spector GJ, et al. Reirradiation of recurrent head and neck cancers. Laryngoscope 1987; 97:85.</a></li><li><a class="nounderline abstract_t">Tanvetyanon T, Padhya T, McCaffrey J, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009; 27:1983.</a></li></ol></div><div id="topicVersionRevision">Topic 3384 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414635" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Individual patients' data meta-analyses in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15277256" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128894" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15128893" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14645636" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496152" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The natural history of patients with squamous cell carcinoma of the hypopharynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12633577" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15599860" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reirradiation of recurrent head and neck cancers with curative intent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21530100" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23098118" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reirradiation for recurrent head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22115554" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24481720" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28899556" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21671479" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414637" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reirradiation in squamous cell head and neck cancer: recent developments and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18544440" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17259930" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The concurrent chemoradiation paradigm--general principles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327857" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16378901" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Biologic basis for combining drugs with radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135312" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708265" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16213104" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025369" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29413274" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639891" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reirradiation of recurrent and second primary head and neck cancer with proton therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27084656" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27325480" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28941560" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36689229" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35393701" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Multicenter study of re-irradiation using carbon-ions for head and neck malignancies after photon radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18556144" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17379449" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Salvage re-irradiation for recurrent head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32437021" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: Meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076812" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25680594" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743686" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A review on re-irradiation for recurrent and second primary head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15752889" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16563995" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Perioperative high-dose-rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: Initial results of a Phase I/II reirradiation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936479" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518815" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11391587" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28259292" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17967302" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385883" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040014" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : High-dose reirradiation of head and neck cancer with curative intent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18286493" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Outcomes following reirradiation of patients with head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736334" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Reirradiation of recurrent head and neck cancers: external and/or interstitial radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3360654" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Salvage irradiation of oropharynx and mobile tongue about 192 iridium brachytherapy in Centre Alexis Vautrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040013" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Salvage irradiation by brachytherapy of velotonsillar squamous cell carcinoma in a previously irradiated field: results in 73 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16721742" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Interstitial low-dose-rate brachytherapy in the treatment of recurrent head and neck malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3597158" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Salvage irradiation of oropharyngeal cancers using iridium 192 wire implants: 5-year results of 70 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567809" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16029806" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19560882" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : High-dose-rate intraoperative radiation therapy for recurrent head-and-neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11380224" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Conformal re-irradiation of recurrent and new primary head-and-neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16524634" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A phase II study of primary reirradiation in squamous cell carcinoma of head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11483328" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2025836" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intraoperative radiation therapy for recurrent head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875950" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27997054" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Stereotactic body radiotherapy for recurrent head and neck cancer: A critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24824359" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27302512" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34269492" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19464819" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477291" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Head and Neck Tumor Control Probability: Radiation Dose-Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764087" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947728" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006741" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728690" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15719391" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15719391" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15719391" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15817346" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093901" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093901" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10487944" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33889760" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Safety of reRT with SBRT plus concurrent and adjuvant pembrolizumab in patients with recurrent or new second primary head and neck squamous cell cancer in a previously irradiated field: RTOG 3507 Foundation (KEYSTROKE)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262821" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22414284" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29784451" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34298628" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346519" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Final results of a multi-institutional phase II trial of reirradiation with concurrent weekly cisplatin and cetuximab for recurrent or second primary squamous cell carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23104721" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12796357" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21330337" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16005577" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407106" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9014691" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Salvage treatment for inoperable neck nodes in head and neck cancer using combined iridium-192 brachytherapy and surgical reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16260054" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246055" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26282714" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32182548" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18846001" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Re-irradiation of head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536844" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30846182" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956946" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Carotid blowout syndrome after reirradiation for head and neck malignancies: a comprehensive systematic review for a pragmatic multidisciplinary approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772844" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The management of carotid artery rupture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21549520" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of carotid blowout after reirradiation of the head and neck: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28865925" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33583641" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Initial Data Pooling for Radiation Dose-Volume Tolerance for Carotid Artery Blowout and Other Bleeding Events in Hypofractionated Head and Neck Retreatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12751931" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Endovascular management of impending carotid rupture in a patient with advanced head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784256" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Results of salvage treatment of the neck in patients with oral cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3597157" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Re-irradiation of recurrent nasopharyngeal carcinoma--treatment techniques and results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8344846" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Re-irradiation of laryngeal carcinoma--techniques and results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31355972" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO-Head and Neck working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3796178" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Reirradiation of recurrent head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289616" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Prognostic factors for survival after salvage reirradiation of head and neck cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
